Dark

Check out our Level2View

OMGA
Omega Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Feb 24, 2025

0.1426USD-10.819%(-0.0173)5,153,596

Pre-market

0.00USD-100.000%(-0.16)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 10, 2022

07:01AM EST Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical PR Newswire

Nov 18, 2021

07:02AM EST Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual PR Newswire

Nov 12, 2021

08:15PM EST 20:15 Friday, November 12, 2021Wedbush (RTTNews) - Wedbush Reiterates Omega Therapeutics, Inc. (OMGA) At Outperform With $36 Price Target RTTNews

Nov 10, 2021

07:38AM EST Omega Therapeutics Q3 EPS $(0.57) Benzinga

07:16AM EST Omega Therapeutics Q3 Loss Per Share $0.57 Vs Loss $1.97 Last Year RTTNews

07:02AM EST Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines PR Newswire

Nov 9, 2021

07:01AM EST Omega Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire

Oct 14, 2021

07:14AM EDT Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine; No Financial Terms Disclosed Benzinga

07:01AM EDT Omega Therapeutics Announces Strategic Research Collaboration with Stanford PR Newswire

Sep 27, 2021

07:01AM EDT Omega Therapeutics to Present at the Chardan Virtual 5th Annual Genetic PR Newswire

Sep 10, 2021

07:49AM EDT Omega Therapeutics Inc. (OMGA) reported that its net loss for the second quarter of 2021 widened to $15.4 million or $3.36 per share, from last year's $6.3 million or $1.58 per share, primarily due to increased research and development and G&A expenses to support the company's growth. RTTNews

07:36AM EDT Omega Therapeutics Q2 Loss Per Share $3.36 Vs Loss $1.58 Last Year RTTNews

07:07AM EDT Omega Therapeutics Q2 Net Loss $15.4 Mln Vs $6.3 Mln Last Year RTTNews

07:04AM EDT Omega Therapeutics Q2 EPS $(3.36), Down From $(1.58) YoY Benzinga

07:01AM EDT Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines PR Newswire

Aug 24, 2021

04:18PM EDT 16:18 Tuesday, August 24, 2021Wedbush (RTTNews) - Wedbush Starts Omega Therapeutics, Inc. (OMGA) At Outperform With $36 Price Target RTTNews

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021 Benzinga

08:33AM EDT Wedbush Initiates Coverage On Omega Therapeutics with Outperform Rating, Announces Price Target of $36 Benzinga

06:07AM EDT Jefferies Initiates Coverage On Omega Therapeutics with Buy Rating, Announces Price Target of $30 Benzinga

05:40AM EDT Piper Sandler Initiates Coverage On Omega Therapeutics with Overweight Rating, Announces Price Target of $30 Benzinga

05:04AM EDT Goldman Sachs Initiates Coverage On Omega Therapeutics with Neutral Rating, Announces Price Target of $22 Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Jul 30, 2021

01:35PM EDT Omega Therapeutics Kicks Start Trading On NASDAQ Benzinga

11:56AM EDT Omega Therapeutics Shares Open For Trade At $22.10; IPO Priced At $17/Share Benzinga

09:14AM EDT Omega Therapeutics Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/Share Benzinga

02:21AM EDT Omega Therapeutics, Inc. (OMGA), a development-stage biotechnology company specializing in epigenetics on Thursday announced $17 per share as the price of its Initial Public Offering (IPO) of 7,400,000 shares. RTTNews

Jul 29, 2021

10:07PM EDT Omega Therapeutics Prices IPO Of 7.40 Mln Shares At $17.00/shr RTTNews

10:00PM EDT Omega Therapeutics Announces Pricing of Initial Public Offering PR Newswire

Share